Phathom Pharmaceuticals (PHAT) Operating Leases (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Operating Leases of $1.9 million for Q2 2026, up 214.94% year-over-year from $589000.0 in Q2 2025, and down 5.41% quarter-over-quarter from $2.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Operating Leases (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Operating Leases for 8 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Leases rose 214.94% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (up 214.94% YoY), while the FY2025 annual figure was $2.1 million, changed N/A from the prior year.
- Operating Leases retreated to $1.9 million in Q2 2026 per PHAT's latest filing, from $2.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $2.1 million in Q3 2025 and bottomed at $133000.0 in Q2 2024.
- Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Leases tumbled 83.14% — and 2025, when it jumped 342.86%.
- Phathom Pharmaceuticals' Operating Leases stood at $1.1 million in 2022, then slumped by 57.92% to $462000.0 in 2023, then slumped by 71.21% to $133000.0 in 2024, then jumped by 1452.63% to $2.1 million in 2025, then fell by 10.17% to $1.9 million in 2026.
- Business Quant data shows PHAT's Operating Leases at $1.9 million in Q2 2026, $2.0 million in Q1 2026, and $2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 589,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 292,000.00 |
| Dec 31, 2023 | 462,000.00 |
| Sep 30, 2023 | 628,000.00 |
| Jun 30, 2023 | 789,000.00 |
| Mar 31, 2023 | 945,000.00 |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 1.38 Mn |
| Mar 31, 2021 | 1.47 Mn |
| Dec 31, 2020 | 1.56 Mn |